News Releases

NEW YORK , March 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,

Total fourth quarter net product sales of $24.4 million Auvelity ® launched October 19th , with fourth quarter net product sales of $5.2 million Sunosi ® fourth quarter net product sales of $19.2 million Sunosi ® license agreement for EU announced – $66 million upfront, potential milestones up to

Axsome to receive an upfront payment of $66 million , and is eligible to receive sales-based and other milestones totaling up to $101 million Pharmanovia is responsible for all ongoing and future clinical studies in Europe and MENA NEW YORK , Feb. 22, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics,

NEW YORK , Feb. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau , MD, Axsome’s Chief Executive Officer,

Axsome to host conference call and webcast on Monday, Feb. 27, 2023, at 8:00 a.m. ET NEW YORK , Jan. 31, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS)